SGLT-2 Inhibitor Decreases Renal Outcomes in Diabetic Patients without Baseline Renal Impairment

Chronic Spontaneous Urticaria: Control in Primary Care

DECLARE-TIMI 58 Sub-analyses: Expanding Evidence of Cardiovascular Protection across Broad Spectrum of Patients

Earlier Treatment Intervention in Heart Failure Patients Results in Improved Outcomes

In Obesity, Brain Circuitry Influences Cravings and Dysregulated Eating

Large PIONEER-HF Trial Validates Safety and Benefits of In-Hospital Initiation of Therapeutic Treatment

DECLARE-TIMI 58: Latest SGLT2 Cardiovascular Trial Supports Benefits beyond Glucose Control

Latebreaker Trial Shows Heart Failure Recovery Is Remission and Not a Cure

For Macular Degeneration, New Data Validates Less Frequent Anti-VEGF Dosing

New Agents and Combinations Promise Improved Glaucoma Control

Treatment Options on the Horizon for Glaucoma Management

Oral JAK Inhibitors May Displace Injectable Biologics in Treatment of Rheumatoid Arthritis